LivaNova PLC reported strong second-quarter 2025 results, with total net revenue increasing 10.7% to $352.5 million, or 10.3% organically, compared to $318.6 million in the second quarter of 2024. Adjusted diluted earnings per share were $1.05, up from $0.93 in the prior-year quarter. The Cardiopulmonary segment revenue increased 14.7% to $199.3 million, driven by strong consumables demand and Essenz Perfusion System sales.
Neuromodulation revenue grew 6.2% to $151.7 million, with growth across all regions. The company's disciplined execution contributed to meaningful operating margin expansion and strong cash generation in the second quarter.
LivaNova raised its full-year 2025 guidance, now expecting revenue growth between 8.0% and 9.0% on a constant-currency basis, or 9.0% to 10.0% organically. Adjusted diluted earnings per share are projected in the range of $3.70 to $3.80, an increase from prior guidance. Adjusted free cash flow is now estimated between $140 million and $160 million, reflecting an improved financial outlook.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.